ZIMMER BIOMET HOLDINGS, INC.

Zimmer Biomet Holdings, Inc. has secured new revolving credit facilities totaling $2.75 billion. This includes a five-year, $1.5 billion facility maturing in 2031 and a 364-day, $1.25 billion facility maturing in 2027. Both agreements are for general corporate purposes and replace previous credit facilities, which were terminated with no principal balance outstanding.

Zimmer Biomet Holdings, Inc. held its annual meeting of shareholders on May 22, 2026. Shareholders elected ten directors for one-year terms and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026. Additionally, shareholders approved, on an advisory basis, the compensation of the company's named executive officers, while rejecting a shareholder proposal for an Independent Board Chairman.

Zimmer Biomet Holdings, Inc. announced its intent to repurchase up to $1.0 billion of its common stock during fiscal year 2026. This amount is a $250 million increase from the company's previously disclosed capital allocation assumptions for the year. The repurchases will be made under the company's existing $1.5 billion share repurchase authorization, which was approved by the Board of Directors in February 2026.

Zimmer Biomet Holdings, Inc. reported strong first-quarter 2026 financial results, with net sales increasing by 9.3% to $2.09 billion and diluted EPS rising 34.1% to $1.22. Operating profit also saw a significant increase of 27.7% to $373.2 million. The company continued its 2025 Restructuring Plan and integrated recent acquisitions of Paragon 28 and Monogram Technologies, which contributed to its segment performance.

Zimmer Biomet Holdings, Inc. announced that Suketu Upadhyay will depart from his role as Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, effective April 28, 2026, to pursue a new professional opportunity. His departure is not due to any disagreement with the company. Paul Stellato, currently Vice President, Controller and Chief Accounting Officer, has been appointed as interim Chief Financial Officer while the company conducts a search for a permanent successor.

Zimmer Biomet Holdings, Inc. reported strong first-quarter 2026 financial results, with net sales increasing 9.3% to $2.087 billion and diluted EPS rising 34.1% to $1.22. Adjusted diluted EPS grew 15.5% to $2.09. The company also updated its full-year 2026 financial guidance, raising its adjusted EPS expectations. These results reflect healthy end markets and momentum from new product launches.